Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2YN1W
|
|||
| Drug Name |
NKTR-255
|
|||
| Indication | Colorectal cancer [ICD-11: 2B91.Z] | Phase 1/2 | [1] | |
| Head and neck cancer [ICD-11: 2D42; ICD-9: 199] | Phase 1/2 | [1] | ||
| Company |
Nektar Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Interleukin 15 receptor alpha (IL15RA) | Target Info | Agonist | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Jak-STAT signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| HTLV-I infection | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| IL1 Signaling Pathway | ||||
| Panther Pathway | Interleukin signaling pathway | |||
| WikiPathways | TCR Signaling Pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04616196) Study of NKTR 255 in Combination With Cetuximab in Solid Tumors. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Nektar Therapeutics. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.